Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Rotmensz

Showing results (21-30 of 100) with videos related to

Pageof 10
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 12, 2010
Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysisS Iodice, M Barile, N Rotmensz, et al.
British Journal of Cancer|September 23, 1998
Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention GroupA Decensi, C Robertson, N Rotmensz, et al.
European Journal of Cancer & Clinical Oncology|June 1, 1987
Phase II trial of anaxirone (1,2,4-triglycidylurazol, TGU) in patients with advanced ovarian carcinoma: an EORTC Gynecological Cancer Cooperative Group StudyM George, V Scotto, F Carnino, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2000
Update on tamoxifen to prevent breast cancer. The Italian Tamoxifen Prevention StudyA Decensi, B Bonanni, N Rotmensz, et al.
Journal of Steroid Biochemistry|December 1, 1985
Aminoglutethimide and estrogenic stimulation before chemotherapy for treatment of advanced breast cancer. Preliminary results of a phase II study conducted by the E.O.R.T.C. Breast Cancer Cooperative GroupR Paridaens, J B Van der Wijst, J P Julien, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)E Engelsman, J C Klijn, R D Rubens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2015
Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancerG Pruneri, A Vingiani, V Bagnardi, et al.
Cancer|September 26, 2001
A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patientsR Biffi, F De Braud, F Orsi, et al.
European Journal of Cancer & Clinical Oncology|January 1, 1982
N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative groupR Paridaens, H T Mouridsen, T Palshof, et al.
The British Journal of Surgery|August 10, 2017
Improved prognosis of young patients with breast cancer undergoing breast-conserving surgeryE Botteri, P Veronesi, J Vila, et al.
Pageof 10

Showing results (21-30 of 100) with videos related to

Sort By:
Pageof 10
European Journal of Cancer (Oxford, England : 1990)|June 12, 2010
Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysisS Iodice, M Barile, N Rotmensz, et al.
British Journal of Cancer|September 23, 1998
Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention GroupA Decensi, C Robertson, N Rotmensz, et al.
European Journal of Cancer & Clinical Oncology|June 1, 1987
Phase II trial of anaxirone (1,2,4-triglycidylurazol, TGU) in patients with advanced ovarian carcinoma: an EORTC Gynecological Cancer Cooperative Group StudyM George, V Scotto, F Carnino, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2000
Update on tamoxifen to prevent breast cancer. The Italian Tamoxifen Prevention StudyA Decensi, B Bonanni, N Rotmensz, et al.
Journal of Steroid Biochemistry|December 1, 1985
Aminoglutethimide and estrogenic stimulation before chemotherapy for treatment of advanced breast cancer. Preliminary results of a phase II study conducted by the E.O.R.T.C. Breast Cancer Cooperative GroupR Paridaens, J B Van der Wijst, J P Julien, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)E Engelsman, J C Klijn, R D Rubens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2015
Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancerG Pruneri, A Vingiani, V Bagnardi, et al.
Cancer|September 26, 2001
A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patientsR Biffi, F De Braud, F Orsi, et al.
European Journal of Cancer & Clinical Oncology|January 1, 1982
N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative groupR Paridaens, H T Mouridsen, T Palshof, et al.
The British Journal of Surgery|August 10, 2017
Improved prognosis of young patients with breast cancer undergoing breast-conserving surgeryE Botteri, P Veronesi, J Vila, et al.
Pageof 10